BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology. 2001;34:529-534. [PMID: 11526539 DOI: 10.1053/jhep.2001.27219] [Cited by in Crossref: 209] [Cited by in F6Publishing: 206] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Park JH, Koh KC, Choi MS, Lee JH, Yoo BC, Paik SW, Rhee JC, Joh JW. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg. 2006;192:29-33. [PMID: 16769271 DOI: 10.1016/j.amjsurg.2005.11.010] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 4.9] [Reference Citation Analysis]
2 Wong VW, Chan SL, Mo F, Chan T, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. JCO 2010;28:1660-5. [DOI: 10.1200/jco.2009.26.2675] [Cited by in Crossref: 290] [Cited by in F6Publishing: 106] [Article Influence: 26.4] [Reference Citation Analysis]
3 Jaruvongvanich V, Sempokuya T, Wong L. Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma? J Gastrointest Oncol 2018;9:750-61. [PMID: 30151272 DOI: 10.21037/jgo.2018.05.11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
4 Cho YK, Chung JW, Kim JK, Ahn YS, Kim MY, Park YO, Kim WT, Byun JH. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer. 2008;112:352-361. [PMID: 18008352 DOI: 10.1002/cncr.23185] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 6.4] [Reference Citation Analysis]
5 Zhao B, Zhang J, Zhang J, Luo R, Wang Z, Xu H, Huang B. Assessment of the 8th edition of TNM staging system for gastric cancer: the results from the SEER and a single-institution database. Future Oncol 2018;14:3023-35. [PMID: 30426787 DOI: 10.2217/fon-2018-0299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
6 Chen TW, Chu CM, Yu JC, Chen CJ, Chan DC, Liu YC, Hsieh CB. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. Eur J Surg Oncol. 2007;33:480-487. [PMID: 17129701 DOI: 10.1016/j.ejso.2006.10.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
7 Urakawa H, Kora SI, Mitsufuji T, Osame A, Higahsihara H, Yoshimitsu K. Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population. Acta Radiol 2016;57:1445-52. [PMID: 26861204 DOI: 10.1177/0284185116628339] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: A review of literature. World J Gastroenterol 2014; 20(15): 4141-4150 [PMID: 24764652 DOI: 10.3748/wjg.v20.i15.4141] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
9 Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology. 2014;86:63-71. [PMID: 24401634 DOI: 10.1159/000356573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Motola-kuba D, Zamora-valdés D, Uribe M, Méndez-sánchez N. Hepatocellular carcinoma. An overview. Annals of Hepatology 2006;5:16-24. [DOI: 10.1016/s1665-2681(19)32034-4] [Cited by in Crossref: 88] [Article Influence: 5.9] [Reference Citation Analysis]
11 Samawi HH, Sim HW, Chan KK, Alghamdi MA, Lee-Ying RM, Knox JJ, Gill P, Romagnino A, Batuyong E, Ko YJ, Davies JM, Lim HJ, Cheung WY, Tam VC; CHORD Consortium. Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. Cancer Med 2018. [PMID: 29766659 DOI: 10.1002/cam4.1493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
12 Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106:1439-1445. [PMID: 22433965 DOI: 10.1038/bjc.2012.92] [Cited by in Crossref: 209] [Cited by in F6Publishing: 216] [Article Influence: 23.2] [Reference Citation Analysis]
13 Chan AW, Chan RC, Wong GL, Wong VW, Choi PC, Chan HL, To KF. New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. J Gastroenterol Hepatol. 2015;30:1391-1396. [PMID: 25753927 DOI: 10.1111/jgh.12938] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 11.8] [Reference Citation Analysis]
14 Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010;53:108-117. [PMID: 20451283 DOI: 10.1016/j.jhep.2010.01.038] [Cited by in Crossref: 106] [Cited by in F6Publishing: 102] [Article Influence: 9.6] [Reference Citation Analysis]
15 Mai RY, Zeng J, Meng WD, Lu HZ, Liang R, Lin Y, Wu GB, Li LQ, Ma L, Ye JZ, Bai T. Artificial neural network model to predict post-hepatectomy early recurrence of hepatocellular carcinoma without macroscopic vascular invasion. BMC Cancer 2021;21:283. [PMID: 33726693 DOI: 10.1186/s12885-021-07969-4] [Reference Citation Analysis]
16 Bargellini I. Hepatocellular carcinoma: MR staging and therapeutic decisions. Abdom Imaging 2012;37:231-8. [PMID: 21479803 DOI: 10.1007/s00261-011-9735-8] [Reference Citation Analysis]
17 Chan AWH, Chong CCN, Mo FKF, Wong J, Yeo W, Johnson PJ, Yu S, Lai PBS, Chan ATC, To K, Chan SL. Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma: Albumin-bilirubin-based Italian staging. Journal of Gastroenterology and Hepatology 2017;32:221-8. [DOI: 10.1111/jgh.13457] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
18 Kang Y, Wang F, Zu H, Yang Z, Xue Y. A New Subclassification of pT4 Gastric Cancers According to the Width of Serosal Invasion. PLoS One 2013;8:e68042. [PMID: 23826361 DOI: 10.1371/journal.pone.0068042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
19 Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'amico F, Ciarleglio FA, Bridda A, Francesco D'amico D. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology 2006;44:723-31. [DOI: 10.1016/j.jhep.2005.12.015] [Cited by in Crossref: 275] [Cited by in F6Publishing: 261] [Article Influence: 18.3] [Reference Citation Analysis]
20 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
21 Chen J, Chen C, He Y, Wu K, Wu H, Cai S. A new pN staging system based on both the number and anatomic location of metastatic lymph nodes in gastric cancer. J Gastrointest Surg 2014;18:2080-8. [PMID: 25297445 DOI: 10.1007/s11605-014-2663-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
22 Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Makuuchi M, Omata M. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54:419-425. [PMID: 15710994 DOI: 10.1136/gut.2003.035055] [Cited by in Crossref: 174] [Cited by in F6Publishing: 166] [Article Influence: 10.9] [Reference Citation Analysis]
23 Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, Hasegawa S, Tsubouchi H;  Kagoshima Liver Cancer Study Group. Surgical resection vs radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg. 2009;16:359-366. [PMID: 19300896 DOI: 10.1007/s00534-009-0069-7] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 7.4] [Reference Citation Analysis]
24 Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481-8. [PMID: 24084770 DOI: 10.1038/bjc.2013.564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
25 Rabe C, Lenz M, Schmitz V, Pilz T, Fimmers R, Sauerbruch T, Caselmann WH. An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2003;15:1305-15. [PMID: 14624154 DOI: 10.1097/00042737-200312000-00009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
26 Peng CW, Wang LW, Zeng WJ, Yang XJ, Li Y. Evaluation of the staging systems for gastric cancer. J Surg Oncol 2013;108:93-105. [PMID: 23813573 DOI: 10.1002/jso.23360] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
27 Kanayama M, Nagai H, Sumino Y. Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009;64:109-114. [PMID: 18979100 DOI: 10.1007/s00280-008-0851-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
28 Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Glória H, Marinho R, Távora I, Ramalho F. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26:680-687. [PMID: 16842324 DOI: 10.1111/j.1478-3231.2006.001285.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
29 Harimoto N, Yoshizumi T, Sakata K, Nagatsu A, Motomura T, Itoh S, Harada N, Ikegami T, Uchiyama H, Soejima Y, Maehara Y. Prognostic significance of combined albumin-bilirubin and tumor-node-metastasis staging system in patients who underwent hepatic resection for hepatocellular carcinoma. Hepatol Res 2017;47:1289-98. [PMID: 28169483 DOI: 10.1111/hepr.12868] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
30 Cheng B, Jia C, Liu C, Lu X, Zhong N, Zhang Z, Fan W, Li Y. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Digestive and Liver Disease 2008;40:446-52. [DOI: 10.1016/j.dld.2007.11.024] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 5.2] [Reference Citation Analysis]
31 Lu LH, Zhang YF, Mu-Yan C, Kan A, Zhong XP, Mei J, Ling YH, Li SH, Shi M, Wei W, Guo RP. Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. Dig Liver Dis. 2019;51:1430-1437. [PMID: 31054962 DOI: 10.1016/j.dld.2019.04.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
32 Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment. Curr Probl Diagn Radiol. 2015;44:479-486. [PMID: 25979220 DOI: 10.1067/j.cpradiol.2015.04.004] [Cited by in Crossref: 80] [Cited by in F6Publishing: 88] [Article Influence: 13.3] [Reference Citation Analysis]
33 Giakoustidis AE, Giakoustidis DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy 2017;9:197-206. [PMID: 28128716 DOI: 10.2217/imt-2016-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Yang T, Zhang J, Lu JH, Yang LQ, Yang GS, Wu MC, Yu WF. A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. J Cancer Res Clin Oncol. 2011;137:739-750. [PMID: 20607551 DOI: 10.1007/s00432-010-0935-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
35 Siddique I, El-Naga HA, Memon A, Thalib L, Hasan F, Al-Nakib B. CLIP score as a prognostic indicator for hepatocellular carcinoma: experience with patients in the Middle East. Eur J Gastroenterol Hepatol. 2004;16:675-680. [PMID: 15201581 DOI: 10.1097/01.meg.0000108338.41221.ec] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
36 Wildi S, Pestalozzi BC, McCormack L, Clavien PA. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004;91:400-8. [PMID: 15048738 DOI: 10.1002/bjs.4554] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
37 Zhou R, Zhang J, Sun H, Liao Y, Liao W. Comparison of three lymph node classifications for survival prediction in distant metastatic gastric cancer. Int J Surg 2016;35:165-71. [PMID: 27713088 DOI: 10.1016/j.ijsu.2016.09.096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
38 Sun Z, Wang ZN, Zhu Z, Xu YY, Xu Y, Huang BJ, Zhu GL, Xu HM. Evaluation of the seventh edition of American Joint Committee on Cancer TNM staging system for gastric cancer: results from a Chinese monoinstitutional study. Ann Surg Oncol. 2012;19:1918-1927. [PMID: 22246426 DOI: 10.1245/s10434-011-2206-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
39 An C, Choi GH, Lee HS, Kim MJ. Assessment of preoperative magnetic resonance imaging staging in patients with hepatocellular carcinoma undergoing resection compared with the seventh American Joint Committee on Cancer System. Invest Radiol 2012;47:634-41. [PMID: 22814590 DOI: 10.1097/RLI.0b013e3182630e8d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
40 Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:23-33. [PMID: 21115578 DOI: 10.1634/theoncologist.2010-s4-23] [Cited by in Crossref: 79] [Cited by in F6Publishing: 47] [Article Influence: 7.9] [Reference Citation Analysis]
41 Iñarrairaegui M, Thurston KG, Bilbao JI, D'avola D, Rodriguez M, Arbizu J, Martinez-cuesta A, Sangro B. Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis. Journal of Vascular and Interventional Radiology 2010;21:1205-12. [DOI: 10.1016/j.jvir.2010.04.012] [Cited by in Crossref: 95] [Cited by in F6Publishing: 97] [Article Influence: 8.6] [Reference Citation Analysis]
42 Addissie BD, Roberts LR. Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making. Clin Liver Dis. 2015;19:277-294. [PMID: 25921663 DOI: 10.1016/j.cld.2015.01.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
43 Endo M, Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. Mol Clin Oncol 2016;4:515-22. [PMID: 27073653 DOI: 10.3892/mco.2016.755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
44 Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouché O, Raoul J, Rougier P, Masskouri F, Bedenne L, Barbare J. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Annals of Oncology 2008;19:1117-26. [DOI: 10.1093/annonc/mdn030] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
45 Seo YS, Kim YJ, Um SH, Yoo H, Lee JW, Kim YS, Jeen YT, Chun HJ, Kim CD, Ryu HS. Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:1267-1275. [PMID: 18637054 DOI: 10.1111/j.1440-1746.2008.05480.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
46 Hashiguchi Y, Hase K, Kotake K, Ueno H, Shinto E, Mochizuki H, Yamamoto J, Sugihara K. Evaluation of the seventh edition of the tumour, node, metastasis (TNM) classification for colon cancer in two nationwide registries of the United States and Japan. Colorectal Dis 2012;14:1065-74. [PMID: 22176600 DOI: 10.1111/j.1463-1318.2011.02917.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
47 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35-41. [PMID: 18333159 DOI: 10.1080/13651820410024058] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 13.9] [Reference Citation Analysis]
48 Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Saeki C, Tajiri H. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 2013;13:52. [PMID: 23374755 DOI: 10.1186/1471-2407-13-52] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
49 Gu P, Deng J, Sun Z, Wang Z, Wang W, Liang H, Xu H, Zhou Z. Superiority of log odds of positive lymph nodes (LODDS) for prognostic prediction after gastric cancer surgery: a multi-institutional analysis of 7620 patients in China. Surg Today 2021;51:101-10. [PMID: 32754844 DOI: 10.1007/s00595-020-02091-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Wang W, Xu D, Li Y, Guan Y, Sun X, Chen Y, Kesari R, Huang C, Li W, Zhan Y, Zhou Z. Tumor–ratio–metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection—results of a single-institution study of 1343 Chinese patients. Annals of Oncology 2011;22:2049-56. [DOI: 10.1093/annonc/mdq716] [Cited by in Crossref: 54] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
51 Li SH, Wang QX, Yang ZY, Jiang W, Li C, Sun P, Wei W, Shi M, Guo RP. Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. World J Gastroenterol 2017; 23(17): 3122-3132 [PMID: 28533669 DOI: 10.3748/wjg.v23.i17.3122] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
52 Zhao JJ, Yan T, Zhao H, Zhou JG, Huang Z, Zhang YF, Li Y, Li ZY, Bi XY, Cai JQ. Evaluation of eight different clinical staging systems associated with overall survival of chinese patients with hepatocellular carcinoma. Chin Med J (Engl) 2015;128:316-21. [PMID: 25635426 DOI: 10.4103/0366-6999.150095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
53 Zhong B, Ni C, Yin G, Chen L, Zhu H, Guo J, He S, Deng G, Zhang Q, Li P, Yu H, Teng G. Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2018;41:1867-76. [DOI: 10.1007/s00270-018-2023-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford). 2003;5:243-250. [PMID: 18332995 DOI: 10.1080/13651820310015833] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 7.7] [Reference Citation Analysis]
55 Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010;24:899-919, viii. [PMID: 20937457 DOI: 10.1016/j.idc.2010.07.004] [Cited by in Crossref: 120] [Cited by in F6Publishing: 111] [Article Influence: 12.0] [Reference Citation Analysis]
56 Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13:S211-S221. [PMID: 12354839 DOI: 10.1016/s1051-0443(07)61789-8] [Cited by in Crossref: 150] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
57 Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005;100:1764-71. [PMID: 16086713 DOI: 10.1111/j.1572-0241.2005.41943.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
58 Chen L, Song L, Shao Y, Li D, Ding K. Using natural language processing to extract clinically useful information from Chinese electronic medical records. Int J Med Inform 2019;124:6-12. [PMID: 30784428 DOI: 10.1016/j.ijmedinf.2019.01.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
59 Zhang YF, Shi M, Lu LH, Wang L, Guo RP. Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. J Hepatocell Carcinoma 2021;8:253-61. [PMID: 33907695 DOI: 10.2147/JHC.S305581] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Adhoute X, Penaranda G, Raoul JL, Bourlière M. Hepatocellular carcinoma scoring and staging systems. Do we need new tools? J Hepatol. 2016;64:1449-1450. [PMID: 26912407 DOI: 10.1016/j.jhep.2016.01.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
61 Farinati F, Sergio A, Giacomin A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F; Italian Liver Cancer group. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol 2009;21:1212-8. [PMID: 19465859 DOI: 10.1097/MEG.0b013e32831a86f8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
62 Kang HY, Shin HD, Kim SB, Song IH. Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area. Clin Res Hepatol Gastroenterol 2012;36:357-64. [PMID: 22326248 DOI: 10.1016/j.clinre.2011.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Nanashima A, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Tsuji T, Hidaka S, Sawai T, Yasutake T, Nakagoe T. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 2003;29:735-42. [DOI: 10.1016/j.ejso.2003.08.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
64 Cheung TK, Lai CL, Wong BC, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24:573-583. [PMID: 16907890 DOI: 10.1111/j.1365-2036.2006.03029.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.4] [Reference Citation Analysis]
65 Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011;117:2478-2488. [PMID: 24048796 DOI: 10.1002/cncr.25791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
66 Xing H, Zhang WG, Cescon M, Liang L, Li C, Wang MD, Wu H, Lau WY, Zhou YH, Gu WM, Wang H, Chen TH, Zeng YY, Schwartz M, Pawlik TM, Serenari M, Shen F, Wu MC, Yang T. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford) 2020;22:677-89. [PMID: 31607637 DOI: 10.1016/j.hpb.2019.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
67 Saito M, Seo Y, Yano Y, Momose K, Hirano H, Yoshida M, Azuma T. Reduction in non-protein respiratory quotient is related to overall survival after hepatocellular carcinoma treatment. PLoS One 2013;8:e55441. [PMID: 23520445 DOI: 10.1371/journal.pone.0055441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
68 Pawlik TM, Tseng JF, Vauthey J. Controversies in the Staging of Hepatocellular Carcinoma. Cancer Rev A P 2003;01:179-89. [DOI: 10.1142/s0219836303000220] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
69 Wang Q, Zhang W, Liu X, Zhang X, He J, Feng Q, Zhou Z, Wang L, Yin W, Xiao Z. Prognosis of esophageal squamous cell carcinoma patients with preoperative radiotherapy: Comparison of different cancer staging systems. Thorac Cancer 2014;5:204-10. [PMID: 26767002 DOI: 10.1111/1759-7714.12079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
70 Daniele B, Perrone F. Staging for Liver Cancer. Clinics in Liver Disease 2005;9:213-23. [DOI: 10.1016/j.cld.2004.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
71 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
72 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
73 Nafteux P, Lerut T, De Hertogh G, Moons J, Coosemans W, Decker G, Van Veer H, De Leyn P. Can extracapsular lymph node involvement be a tool to fine-tune pN1 for adenocarcinoma of the oesophagus and gastro-oesophageal junction in the Union Internationale contre le Cancer (UICC) TNM 7th edition? European Journal of Cardio-Thoracic Surgery 2014;45:1001-10. [DOI: 10.1093/ejcts/ezt546] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
74 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7(3): 406-424 [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 11.3] [Reference Citation Analysis]
75 Yang ZL, Zhu MH, Han XJ, Liu QW, Long JH, Wang CX. Modified American Joint Committee on Cancer Tumor-Node-Metastasis Staging System Based on the Node Ratio Can Further Improve the Capacity of Prognosis Assessment for Gastric Cancer Patients. Front Oncol 2019;9:329. [PMID: 31131256 DOI: 10.3389/fonc.2019.00329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Tong JH, Sun Z, Zhu Z, Wang ZN, Xu YY, Huang BJ, Xu Y, Xu HM. Prognostic significance of lymph node station 7 for patients with gastric cancers underwent radical surgery. J Surg Oncol 2012;105:805-12. [PMID: 22212911 DOI: 10.1002/jso.23011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
77 Strazzabosco M, Cohen E, Emre S. Prognostic prediction in hepatocellular carcinoma: from art to science. J Clin Gastroenterol 2008;42:221-3. [PMID: 18223506 DOI: 10.1097/MCG.0b013e31815ed0a9] [Reference Citation Analysis]
78 Zhang M, Ding C, Xu L, Ou B, Feng S, Wang G, Wang W, Liang Y, Chen Y, Zhou Z, Qiu H. Comparison of a Tumor-Ratio-Metastasis Staging System and the 8th AJCC TNM Staging System for Gastric Cancer. Front Oncol 2021;11:595421. [PMID: 34307116 DOI: 10.3389/fonc.2021.595421] [Reference Citation Analysis]
79 Xiao LB, Yu JX, Wu WH, Xu FF, Yang SB. Superiority of metastatic lymph node ratio to the 7th edition UICC N staging in gastric cancer. World J Gastroenterol 2011; 17(46): 5123-5130 [PMID: 22171148 DOI: 10.3748/wjg.v17.i46.5123] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
80 Chen Y, Zhang G, Zhao B, Huang C, Ling Y, Li Y, Zhou Z. A better prognostic stratification for the 8th edition of the AJCC staging system of gastric cancer by incorporating pT4aN0M0 into stage IIIA. Surg Oncol 2019;29:90-6. [PMID: 31196500 DOI: 10.1016/j.suronc.2019.03.005] [Reference Citation Analysis]
81 Wu J, Zhu P, Zhang Z, Zhang B, Shu C, Chen L, Feng R, Mba'nbo Koumpa AA, Li G, Ge Q. A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy. Cancer Biol Med 2018;15:415-24. [PMID: 30766751 DOI: 10.20892/j.issn.2095-3941.2018.0095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
82 Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients. Eur J Cancer. 2009;45:1630-1639. [PMID: 19157858 DOI: 10.1016/j.ejca.2008.12.025] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
83 Liu H, Deng J, Zhang R, Hao X, Jiao X, Liang H. The RML of lymph node metastasis was superior to the LODDS for evaluating the prognosis of gastric cancer. International Journal of Surgery 2013;11:419-24. [DOI: 10.1016/j.ijsu.2013.03.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
84 Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D'amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'amico DF. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? Journal of Hepatology 2004;40:124-31. [DOI: 10.1016/j.jhep.2003.09.027] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 7.8] [Reference Citation Analysis]
85 Lee CM, Cho JM, Jang YJ, Park SS, Park SH, Kim SJ, Mok YJ, Kim CS, Kim JH. Should lymph node micrometastasis be considered in node staging for gastric cancer?: the significance of lymph node micrometastasis in gastric cancer. Ann Surg Oncol 2015;22:765-71. [PMID: 25201506 DOI: 10.1245/s10434-014-4073-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
86 Zhu M, Zhang K, Yang Z, Qiao Z, Chen L. Comparing prognostic values of the 7th and 8th editions of the American Joint Committee on Cancer TNM staging system for gastric cancer. Int J Biol Markers 2020;35:26-32. [DOI: 10.1177/1724600819891585] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Wang W, Li Y, Zhang Y, Yuan X, Xu D, Guan Y, Feng X, Chen Y, Sun X, Li W. Incorporation of extranodal metastasis of gastric carcinoma into the 7th edition UICC TNM staging system. PLoS One. 2011;6:e19557. [PMID: 21695186 DOI: 10.1371/journal.pone.0019557] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
88 Chan AW, Kumada T, Toyoda H, Tada T, Chong CC, Mo FK, Yeo W, Johnson PJ, Lai PB, Chan AT, To KF, Chan SL. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1300-1306. [PMID: 26751608 DOI: 10.1111/jgh.13291] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 15.5] [Reference Citation Analysis]
89 Cho YK. Re: Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 2007;18:455; author reply 455-6. [PMID: 17377196 DOI: 10.1016/j.jvir.2006.12.738] [Reference Citation Analysis]
90 Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, Iacono C. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597-604. [PMID: 17970836 DOI: 10.1111/j.1572-0241.2007.01604.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.0] [Reference Citation Analysis]
91 Zhang L, Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zhao XM. A microRNA-based prediction model for lymph node metastasis in hepatocellular carcinoma. Oncotarget 2016;7:3587-98. [PMID: 26657296 DOI: 10.18632/oncotarget.6534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
92 Whang-peng J, Cheng A, Hsu C, Chen C. Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. Journal of Experimental & Clinical Medicine 2010;2:93-103. [DOI: 10.1016/s1878-3317(10)60016-2] [Cited by in Crossref: 18] [Article Influence: 1.6] [Reference Citation Analysis]
93 Perry JF, Charlton B, Koorey DJ, Waugh RC, Gallagher PJ, Crawford MD, Verran DJ, McCaughan GW, Strasser SI. Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. Liver Int. 2007;27:1240-1248. [PMID: 17919236 DOI: 10.1111/j.1478-3231.2007.01569.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
94 Liu F, Zhou R, Jiang F, Liu G, Li K, Zhu G. Proposal of a Nomogram for Predicting Survival in Patients with Siewert Type II Adenocarcinoma of the Esophagogastric Junction After Preoperative Radiation. Ann Surg Oncol 2019;26:1292-300. [PMID: 30805805 DOI: 10.1245/s10434-019-07237-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
95 Nafteux PR, Lerut AM, Moons J, Hölscher AH, Bollschweiler E, van Berge Henegouwen MI, Lagarde SM, van Lanschot JJ, Messager M, Mariette C, D'Journo XB, Thomas PA, De Leyn PR. International Multicenter Study on the Impact of Extracapsular Lymph Node Involvement in Primary Surgery Adenocarcinoma of the Esophagus on Overall Survival and Staging Systems. Ann Surg 2015;262:809-15; discussion 815-6. [PMID: 26583670 DOI: 10.1097/SLA.0000000000001463] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 3.4] [Reference Citation Analysis]
96 Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-8. [PMID: 15710992 DOI: 10.1136/gut.2004.048124] [Cited by in Crossref: 173] [Cited by in F6Publishing: 163] [Article Influence: 10.8] [Reference Citation Analysis]
97 Ren Y, Zhang L, Xie H, She Y, Su H, Xie D, Zheng H, Zhang L, Jiang G, Wu C, Dai C, Chen C. Lymph Node Micrometastasis Prognosticates Survival for Patients with Stage 1 Bronchogenic Adenocarcinoma. Ann Surg Oncol 2018;25:3812-9. [DOI: 10.1245/s10434-018-6743-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
98 Bruix J, Llovet JM. Prognostic prediction in HCC: Did anybody expect it to be easy? Hepatology 2004;39:551-2. [DOI: 10.1002/hep.20050] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
99 Dilou N, Patouillard B, Audigier JC. [Staging systems in hepatocellular carcinoma]. Gastroenterol Clin Biol 2004;28:359-66. [PMID: 15146151 DOI: 10.1016/s0399-8320(04)94936-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
100 Lee CC, Ho HC, Su YC, Lee MS, Hung SK, Chen YL. The Prognostic Ability of Log Odds of Positive Lymph Nodes in Oral Cavity Squamous Cell Carcinoma. Medicine (Baltimore) 2015;94:e1069. [PMID: 26166079 DOI: 10.1097/MD.0000000000001069] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
101 Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T, Tanaka S, Hai S, Yamamoto S, Ichikawa T, Kodai S, Hirohashi K. Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score. J Gastroenterol 2005;40:972-9. [PMID: 16261434 DOI: 10.1007/s00535-005-1681-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
102 Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, Lu SN. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007;120:2650-2655. [PMID: 17304512 DOI: 10.1002/ijc.22616] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 5.3] [Reference Citation Analysis]
103 Van Deusen MA, Abdalla EK, Vauthey JN, Roh MS. Staging classifications for hepatocellular carcinoma. Expert Rev Mol Diagn 2005;5:377-83. [PMID: 15934814 DOI: 10.1586/14737159.5.3.377] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
104 Kummar S, Shafi NQ. Metastatic hepatocellular carcinoma. Clin Oncol (R Coll Radiol). 2003;15:288-294. [PMID: 12924460 DOI: 10.1016/S0936-6555(03)00067-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
105 Olthoff KM, Forner A, Hübscher S, Fung J. What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? Liver Transpl. 2011;17 Suppl 2:S26-S33. [PMID: 21656653 DOI: 10.1002/lt.22352] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
106 Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, Loong CC, Chiang JH, Huo TI, Lee SD. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer. 2010;116:3006-3014. [PMID: 20564406 DOI: 10.1002/cncr.25044] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 5.8] [Reference Citation Analysis]
107 Cammà C, Di Marco V, Cabibbo G, Latteri F, Sandonato L, Parisi P, Enea M, Attanasio M, Galia M, Alessi N, Licata A, Latteri MA, Craxì A. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008;28:62-75. [PMID: 18373636 DOI: 10.1111/j.1365-2036.2008.03692.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 4.0] [Reference Citation Analysis]
108 Chan AW, Chan SL, Mo FK, Wong GL, Wong VW, Cheung YS, Chan HL, Yeo W, Lai PB, To KF. Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. Dis Markers. 2015;2015:564057. [PMID: 25737613 DOI: 10.1155/2015/564057] [Cited by in Crossref: 38] [Cited by in F6Publishing: 51] [Article Influence: 6.3] [Reference Citation Analysis]
109 Yoon HM, Ryu KW, Nam BH, Cho SJ, Park SR, Lee JY, Lee JH, Kook MC, Choi IJ, Kim YW. Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer? J Am Coll Surg. 2012;214:88-96. [PMID: 22036661 DOI: 10.1016/j.jamcollsurg.2011.09.018] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
110 Mahady SE, Charlton B, Fitzgerald P, Koorey DJ, Perry JF, Waugh RC, McCaughan GW, Strasser SI. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage? J Gastroenterol Hepatol 2010;25:1299-305. [PMID: 20594260 DOI: 10.1111/j.1440-1746.2010.06267.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
111 Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011;80:373-381. [PMID: 21822028 DOI: 10.1159/000329040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
112 Ikai I, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, Makuuchi M, Kojiro M, Ichida T, Arii S. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:884-892. [PMID: 17048053 DOI: 10.1007/s00535-006-1878-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
113 Dohmen K. Many staging systems for hepatocellular carcinoma: Evolution from Child-Pugh, Okuda to SLiDe. J Gastroenterol Hepatol 2004;19:1227-32. [DOI: 10.1111/j.1440-1746.2004.03538.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
114 Chan SL, Chan AW, Chan AK, Jian P, Mo F, Chan CM, Mok K, Liu C, Chong CC, Chan AT, Mok T, Yeo W. Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver Int 2017;37:280-9. [DOI: 10.1111/liv.13218] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
115 Lee PC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC, Huang YH. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. Liver Int. 2018;38:321-330. [PMID: 28736952 DOI: 10.1111/liv.13527] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
116 Ji X, Bu ZD, Yan Y, Li ZY, Wu AW, Zhang LH, Zhang J, Wu XJ, Zong XL, Li SX, Shan F, Jia ZY, Ji JF. The 8th edition of the American Joint Committee on Cancer tumor-node-metastasis staging system for gastric cancer is superior to the 7th edition: results from a Chinese mono-institutional study of 1663 patients. Gastric Cancer. 2018;21:643-652. [PMID: 29168120 DOI: 10.1007/s10120-017-0779-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
117 Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BB, Leung TW, Lai PB, Chan AT. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol. 2011;26:340-347. [PMID: 21261725 DOI: 10.1111/j.1440-1746.2010.06329.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
118 Kung J, Macdougall M, Madhavan K, Garden O, Parks R. Predicting survival in patients with hepatocellular carcinoma: A UK perspective. European Journal of Surgical Oncology (EJSO) 2007;33:188-94. [DOI: 10.1016/j.ejso.2006.10.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
119 Lin J, Fang T, Zhu M, Xu X, Zhang J, Zheng S, Jing C, Zhang M, Liu B, Zhang B. Comparative performance of inflammation-based prognostic scores in patients operated for intrahepatic cholangiocarcinoma. Cancer Manag Res 2019;11:9107-19. [PMID: 31802940 DOI: 10.2147/CMAR.S198959] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
120 Giannini E, Risso D, Botta F, Romagnoli P, Malfatti F, Fumagalli A, Testa E, Podestà E, Chiarbonello B, Polegato S, Testa R. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. J Intern Med 2004;255:399-408. [PMID: 14871465 DOI: 10.1046/j.1365-2796.2003.01284.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
121 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 2.8] [Reference Citation Analysis]
122 Liu C, Duan LG, Lu WS, Yan LN, Xiao GQ, Jiang L, Yang J, Yang JY. Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. PLoS One 2014;9:e103228. [PMID: 25133493 DOI: 10.1371/journal.pone.0103228] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
123 Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF, Lu SN. Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center. Dig Dis Sci. 2013;58:2721-2728. [PMID: 23703450 DOI: 10.1007/s10620-013-2716-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
124 Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510. [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 200] [Article Influence: 15.3] [Reference Citation Analysis]
125 Borzio M, Colloredo G, Pioltelli P, Quagliuolo M. Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis. 2007;39:1011-1017. [PMID: 17936698 DOI: 10.1016/j.dld.2007.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
126 Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, Yan S, Wu L, Geng L, Ke Q, Gao F, Tu Z, Wang W, Zhang M, Shen Y, Xie H, Jiang W, Wang H, Zheng S. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 2016;65:1035-1041. [PMID: 25804634 DOI: 10.1136/gutjnl-2014-308513] [Cited by in Crossref: 83] [Cited by in F6Publishing: 90] [Article Influence: 13.8] [Reference Citation Analysis]
127 Yamagiwa K, Shiraki K, Yamakado K, Mizuno S, Hori T, Yagi S, Hamada T, Iida T, Nakamura I, Fujii K, Usui M, Isaji S, Ito K, Tagawa S, Takeda K, Yokoi H, Noguchi T. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. J Gastroenterol Hepatol. 2008;23:482-490. [PMID: 18086115 DOI: 10.1111/j.1440-1746.2007.05262.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
128 Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World J Gastroenterol 2017; 23(14): 2545-2555 [PMID: 28465639 DOI: 10.3748/wjg.v23.i14.2545] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
129 Hsu PK, Wu YC, Chou TY, Huang CS, Hsu WH. Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma. Ann Thorac Surg. 2010;89:1024-1031. [PMID: 20338302 DOI: 10.1016/j.athoracsur.2010.01.017] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 8.1] [Reference Citation Analysis]
130 Liu PH, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, Lee FY, Lin HC, Huo TI. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol. 2016;64:601-608. [PMID: 26551516 DOI: 10.1016/j.jhep.2015.10.029] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
131 Burns JM, Greene FL. Controversies in staging of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2005;12:456-62. [DOI: 10.1007/s00534-005-1030-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
132 Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. J Surg Oncol. 2011;103:801-806. [PMID: 21240991 DOI: 10.1002/jso.21857] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
133 Pascual S, Zapater P, Such J, Garcia-herola A, Sempere L, Irurzun J, Palazon JM, Carnicer F, Perez-mateo M. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 2006;26:673-9. [DOI: 10.1111/j.1478-3231.2006.01282.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
134 Edeline J, Blanc JF, Johnson P, Campillo-Gimenez B, Ross P, Ma YT, King J, Hubner RA, Sumpter K, Darby S, Evans J, Iwuji C, Swinson D, Collins P, Patel K, Muazzam I, Palmer DH, Meyer T. A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver Int. 2016;36:1821-1828. [PMID: 27214151 DOI: 10.1111/liv.13170] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
135 Kim NY, Sun JM, Kim YJ, Lee KW, Kim JH, Bang SM, Kim JW, Jeong SH, Lee JS. Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era. Cancer Res Treat 2010;42:203-9. [PMID: 21253322 DOI: 10.4143/crt.2010.42.4.203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
136 Liu PH, Hsia CY, Lee YH, Hsu CY, Huang YH, Su CW, Lee RC, Lin HC, Huo TI. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. J Surg Oncol. 2015;111:404-409. [PMID: 25643842 DOI: 10.1002/jso.23854] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
137 Kim KM, Sinn DH, Jung SH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? Liver Int. 2016;36:1490-1497. [PMID: 26936471 DOI: 10.1111/liv.13107] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
138 Vitale A, Farinati F, Finotti M, Di Renzo C, Brancaccio G, Piscaglia F, Cabibbo G, Caturelli E, Missale G, Marra F, Sacco R, Giannini EG, Trevisani F, Cillo U, Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group, Italian Liver Cancer Ita Li Ca Study Group. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers (Basel) 2021;13:1673. [PMID: 33918125 DOI: 10.3390/cancers13071673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Donohoe CL, O'farrell NJ, Grant T, King S, Clarke L, Muldoon C, Reynolds JV. Classification of Pathologic Response to Neoadjuvant Therapy in Esophageal and Junctional Cancer: Assessment of Existing Measures and Proposal of a Novel 3-Point Standard. Annals of Surgery 2013;258:784-92. [DOI: 10.1097/sla.0b013e3182a66588] [Cited by in Crossref: 52] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
140 Zhang J, Zou S, Luo R, Zhu Z, Xu H, Huang B. Proposal of a novel stage grouping of the Eighth Edition of American Joint Committee on Cancer TNM Staging System for Gastric Cancer: results from a retrospective study of 30 years clinical data from a single institute in China. Expert Rev Gastroenterol Hepatol 2020;14:55-64. [PMID: 31062631 DOI: 10.1080/17474124.2019.1613152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
141 Contreras CM, Vauthey JN. Staging systems: Is there a surgical staging and a medical one? A surgeon's perspective. J Hepatobiliary Pancreat Sci 2010;17:438-9. [PMID: 19882373 DOI: 10.1007/s00534-009-0243-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
142 Han K, Lee JT, Seong J. Treatment of non-resectable hepatocellular carcinoma: Non-resectable HCC. Journal of Gastroenterology and Hepatology 2002;17:S424-7. [DOI: 10.1046/j.1440-1746.17.s3.39.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
143 Yang YS, Hu WP, Wang WP, Yuan Y, Chen LQ. Prognostic power of lymph node station ratio for resected esophageal squamous cell carcinoma patients deserves additional investigation. J Surg Oncol 2018;118:49. [PMID: 29878353 DOI: 10.1002/jso.25084] [Reference Citation Analysis]
144 Memon K, Kulik LM, Lewandowski RJ, Wang E, Wang J, Ryu RK, Hickey R, Vouche M, Baker T, Ganger D. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol. 2014;25:1056-1066. [PMID: 24613269 DOI: 10.1016/j.jvir.2014.01.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
145 Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
146 Zhou YX, Yang LP, Wang ZX, He MM, Yun JP, Zhang DS, Wang F, Xu RH. Lymph node staging systems in patients with gastric cancer treated with D2 resection plus adjuvant chemotherapy. J Cancer 2018;9:660-6. [PMID: 29556323 DOI: 10.7150/jca.22016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
147 Tournoux-Facon C, Paoletti X, Barbare JC, Bouché O, Rougier P, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Bedenne L. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol. 2011;54:108-114. [PMID: 21047696 DOI: 10.1016/j.jhep.2010.06.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
148 Huang MA, Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2002;18:345-50. [DOI: 10.1097/00001574-200205000-00008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
149 Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707-716. [PMID: 15795889 DOI: 10.1002/hep.20636] [Cited by in Crossref: 443] [Cited by in F6Publishing: 406] [Article Influence: 27.7] [Reference Citation Analysis]
150 Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg. 2006;202:155-168. [PMID: 16377509 DOI: 10.1016/j.jamcollsurg.2005.06.263] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
151 Nanashima A, Sumida Y, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Ide N, Sawai T, Yasutake T, Nakagoe T. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol. 2004;30:765-770. [PMID: 15296991 DOI: 10.1016/j.ejso.2004.05.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
152 Chan AW, Chong CC, Mo FK, Wong J, Yeo W, Johnson PJ, Yu S, Lai PB, Chan AT, To KF, Chan SL. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1766-1772. [PMID: 26992142 DOI: 10.1111/jgh.13339] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
153 Lin SD, Endo R, Kuroda H, Kondo K, Miura Y, Takikawa Y, Kato A, Suzuki K. Plasma and urine levels of urinary trypsin inhibitor in patients with chronic liver diseases and hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:327-32. [PMID: 14748881 DOI: 10.1111/j.1440-1746.2003.03221.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
154 Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatology Research 2007;37:S206-9. [DOI: 10.1111/j.1872-034x.2007.00186.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
155 Zhao WH, Ma ZM, Zhou XR, Feng YZ, Fang BS. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol 2002; 8(2): 237-242 [PMID: 11925599 DOI: 10.3748/wjg.v8.i2.237] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 2.7] [Reference Citation Analysis]
156 Cai BB, Shi KQ, Li P, Chen BC, Shi L, Johnson PJ, Lai P, Toyoda H, Zhou MT. A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection. Clin Chim Acta 2018;485:187-94. [PMID: 29908940 DOI: 10.1016/j.cca.2018.06.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
157 Shindoh J, Vauthey JN. Staging of biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:313-322. [PMID: 24560112 DOI: 10.1016/j.soc.2013.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
158 Wang W, Sun XW, Li CF, Lv L, Li YF, Chen YB, Xu DZ, Kesari R, Huang CY, Li W, Zhan YQ, Zhou ZW. Comparison of the 6th and 7th editions of the UICC TNM staging system for gastric cancer: results of a Chinese single-institution study of 1,503 patients. Ann Surg Oncol. 2011;18:1060-1067. [PMID: 21107742 DOI: 10.1245/s10434-010-1424-2] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 6.0] [Reference Citation Analysis]
159 Shouval D. HCC: what's the score. Gut 2002;50:749-50. [PMID: 12010872 DOI: 10.1136/gut.50.6.749] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
160 Li S, Li X, Zhang Y, Zhou H, Tang F, Jia Y, Hu T, Sun H, Yang R, Chen Y, Cheng X, Lv W, Wu L, Zhou J, Wang S, Huang K, Wang L, Yao Y, Yang Q, Yang X, Zhang Q, Han X, Lin Z, Xing H, Qu P, Cai H, Song X, Tian X, Shen J, Xi L, Li K, Deng D, Wang H, Wang C, Wu M, Zhu T, Chen G, Gao Q, Wang S, Hu J, Kong B, Xie X, Ma D. Development and validation of a surgical-pathologic staging and scoring system for cervical cancer. Oncotarget 2016;7:21054-63. [PMID: 27014971 DOI: 10.18632/oncotarget.8245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
161 Gan W, Huang JL, Zhang MX, Fu YP, Yi Y, Jing CY, Fan J, Zhou J, Qiu SJ. New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. J Surg Oncol 2018;117:1540-7. [PMID: 29572833 DOI: 10.1002/jso.25046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
162 Deng Y, Pang Q, Miao RC, Chen W, Zhou YY, Bi JB, Liu SS, Zhang JY, Qu K, Liu C. Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma. Onco Targets Ther 2016;9:5317-28. [PMID: 27601923 DOI: 10.2147/OTT.S109736] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
163 Ribero D, Abdalla EK, Thomas MB, Vauthey JN. Liver resection in the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther 2006;6:567-79. [PMID: 16613544 DOI: 10.1586/14737140.6.4.567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
164 Baba Y, Hayashi S, Ueno K, Nakajo M, Ueno S, Kubo F, Baba Y, Hamanoue M, Hasegawa S, Tsubouchi H, Komorizono Y. Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma. Oncol Lett 2010;1:905-11. [PMID: 22966404 DOI: 10.3892/ol_00000161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
165 Limquiaco JL, Wong GL, Wong VW, Lai PB, Chan HL. Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:63-69. [PMID: 19054256 DOI: 10.1111/j.1440-1746.2008.05701.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
166 Zahoor H, Luketich JD, Weksler B, Winger DG, Christie NA, Levy RM, Gibson MK, Davison JM, Nason KS. The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma. Am J Surg 2015;210:610-7. [PMID: 26188709 DOI: 10.1016/j.amjsurg.2015.05.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
167 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23:445-452. [PMID: 17683486 DOI: 10.1111/j.1440-1746.2007.05075.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
168 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T. Review of current staging systems for hepatocellular carcinoma. Hepatology Research 2007;37:S210-5. [DOI: 10.1111/j.1872-034x.2007.00187.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
169 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016; 8(17): 703-715 [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
170 Ferraro D, Consonni D, Fini N, Fasano A, Del Giovane C, Mandrioli J; Emilia Romagna Registry for ALS (ERRALS) Group. Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study. Eur J Neurol 2016;23:1426-32. [DOI: 10.1111/ene.13053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
171 Chen C, Liu P, Lee Y, Tsai Y, Hsu C, Huang Y, Chiou Y, Huo T. Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation: Radiofrequency ablation in renal insufficiency. J Gastroenterol Hepatol 2015;30:192-8. [DOI: 10.1111/jgh.12669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
172 Huang BS, Tsang NM, Lin SM, Lin DY, Lien JM, Lin CC, Chen WT, Chen WY, Hong JH. High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities. Oncol Lett 2013;6:1514-20. [PMID: 24179551 DOI: 10.3892/ol.2013.1582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
173 Lee YH, Hsu CY, Huang YH, Su CW, Lin HC, Hsia CY, Huo TI. α-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma. J Gastrointest Surg 2013;17:730-8. [PMID: 23188220 DOI: 10.1007/s11605-012-2081-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
174 Zhou J, Yan T, Bi X, Zhao H, Huang Z, Zhang Y, Li Y, Feng L, Wang J, Cai J. Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy. Tumour Biol. 2013;34:1061-1070. [PMID: 23322323 DOI: 10.1007/s13277-013-0646-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
175 Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol. 2017;15:746-755.e4. [PMID: 27847278 DOI: 10.1016/j.cgh.2016.10.036] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
176 Nagai H, Kanayama M, Higami K, Momiyama K, Ikoma A, Okano N, Matsumaru K, Watanabe M, Ishii K, Sumino Y, Miki K. Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 2007; 13(2): 280-284 [PMID: 17226909 DOI: 10.3748/wjg.v13.i2.280] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
177 Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:989-994. [PMID: 21820396 DOI: 10.1016/j.cgh.2011.07.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
178 Lin CY, Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009;29:74-81. [PMID: 18331238 DOI: 10.1111/j.1478-3231.2008.01702.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
179 Bialecki ES, Di Bisceglie AM. Clinical presentation and natural course of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2005;17:485-9. [DOI: 10.1097/00042737-200505000-00003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
180 Chan SL, Wong LL, Chan KA, Chow C, Tong JH, Yip TC, Wong GL, Chong CC, Liu PH, Chu CM, Wong VW, To KF, Reeves HL, Chan AW. Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. Liver Cancer 2020;9:167-81. [PMID: 32399431 DOI: 10.1159/000504252] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
181 Wu J, Zhang Z, Zhu P, Mba'nbo-koumpa A, Zhang B, Chen X, Shu C, Zhang W, Feng R, Li G. Comparative liver function models for ruptured hepatocellular carcinoma: A 10-year single center experience. Asian Journal of Surgery 2019;42:874-82. [DOI: 10.1016/j.asjsur.2018.12.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
182 Sasaki R, Murata S, Oda T, Ohkohchi N, Takeda Y, Wakabayashi G. Evaluation of UICC-TNM and JSBS staging systems for surgical patients with extrahepatic cholangiocarcinoma. Langenbecks Arch Surg 2010;395:615-23. [PMID: 20358381 DOI: 10.1007/s00423-010-0640-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
183 Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, Paul PG, Ooi BS, Chung YF, Wong WK. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol. 2008;15:2153-2163. [PMID: 18546045 DOI: 10.1245/s10434-008-9969-z] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 6.1] [Reference Citation Analysis]
184 Hsia Y, Yeh CY, Wei YH, Chen LW, Liao SL. Eyelid sebaceous carcinoma: Validation of the 8th edition of the American Joint Committee on cancer T staging system and the prognostic factors for local recurrence, nodal metastasis, and survival. Eye (Lond) 2019;33:887-95. [PMID: 31147618 DOI: 10.1038/s41433-019-0454-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
185 Bonnetain F, Paoletti X, Collette S, Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Barbare JC, Bedenne L. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res 2008;17:831-43. [PMID: 18618292 DOI: 10.1007/s11136-008-9365-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
186 Sun Z, Wang ZN, Xu YY, Zhu GL, Huang BJ, Xu Y, Liu FN, Zhu Z, Xu HM. Prognostic significance of tumor deposits in gastric cancer patients who underwent radical surgery. Surgery. 2012;151:871-881. [PMID: 22386276 DOI: 10.1016/j.surg.2011.12.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
187 Ray Kim W. The Clip score: is it time to be clipped away? Liver Int 2009;29:2-3. [PMID: 19120937 DOI: 10.1111/j.1478-3231.2008.01913.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
188 Simonetti RG, Gluud C, Pagliaro L; Cochrane Hepato-Biliary Group. Interferon for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2021;2021. [DOI: 10.1002/14651858.cd003883] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
189 Wu SG, Sun JY, Yang LC, Zhou J, Li FY, Li Q, Lin HX, Lin Q, He ZY. Prognosis of patients with esophageal squamous cell carcinoma after esophagectomy using the log odds of positive lymph nodes. Oncotarget 2015;6:36911-22. [PMID: 26426993 DOI: 10.18632/oncotarget.5366] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
190 Shen H, Agarwal D, Qi R, Chalasani N, Liangpunsakul S, Lumeng L, Yoo H, Kwo P. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther. 2007;26:393-400. [PMID: 17635374 DOI: 10.1111/j.1365-2036.2007.03395.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
191 Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-1405. [PMID: 15565571 DOI: 10.1002/hep.20486] [Cited by in Crossref: 243] [Cited by in F6Publishing: 236] [Article Influence: 14.3] [Reference Citation Analysis]
192 Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122:1609-1619. [PMID: 12016426 DOI: 10.1053/gast.2002.33411] [Cited by in Crossref: 374] [Cited by in F6Publishing: 363] [Article Influence: 19.7] [Reference Citation Analysis]
193 Weinberg BD, Patel RB, Wu H, Blanco E, Barnett CC, Exner AA, Saidel GM, Gao J. Model simulation and experimental validation of intratumoral chemotherapy using multiple polymer implants. Med Biol Eng Comput 2008;46:1039-49. [PMID: 18523817 DOI: 10.1007/s11517-008-0354-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
194 Ke B, Song XN, Liu N, Zhang RP, Wang CL, Liang H. Prognostic value of the lymph node ratio in stage III gastric cancer patients undergoing radical resection. PLoS One. 2014;9:e96455. [PMID: 24811256 DOI: 10.1371/journal.pone.0096455] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
195 Dvorchik I, Carr BI. A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. Cancer Detection and Prevention 2007;31:154-60. [DOI: 10.1016/j.cdp.2007.02.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
196 Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS, Ahn SH. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 2011;47:2568-2575. [PMID: 21835608 DOI: 10.1016/j.ejca.2011.07.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
197 Xiang ZL, Zeng ZC, Fan J, Wu WZ, He J, Zeng HY, Tang ZY. A clinicopathological model to predict bone metastasis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2011;137:1791-7. [PMID: 21915751 DOI: 10.1007/s00432-011-1060-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
198 Wong GLH, Wong VWS. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 2013; 19(39): 6515-6522 [PMID: 24151375 DOI: 10.3748/wjg.v19.i39.6515] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
199 Mikami E, Kanno N, Ueno Y, Shimosegawa T. Retrospective evaluation of tumor-mass-reduction therapy for the prognosis of recurrent hepatocellular carcinoma. Hepatol Int 2007;1:460-8. [PMID: 19669343 DOI: 10.1007/s12072-007-9021-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
200 Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, Lee KU, Chung JW, Park JH, Kim CY. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol. 2002;20:4459-4465. [PMID: 12431969 DOI: 10.1200/jco.2002.02.013] [Cited by in Crossref: 86] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
201 Zhao M, Wang JP, Pan CC, Li W, Huang ZL, Zhang L, Fang WJ, Jiang Y, Li XS, Wu PH. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. Eur J Radiol 2012;81:2717-25. [PMID: 22245655 DOI: 10.1016/j.ejrad.2011.10.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
202 Lenze NR, Farquhar DR, Sheth S, Zevallos JP, Lumley C, Blumberg J, Patel S, Hackman T, Weissler MC, Yarbrough WG, Olshan AF, Zanation AM. Prognostic impact of socioeconomic status compared to overall stage for HPV-negative head and neck squamous cell carcinoma. Oral Oncol 2021;119:105377. [PMID: 34161897 DOI: 10.1016/j.oraloncology.2021.105377] [Reference Citation Analysis]
203 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
204 Guglielmi A, Ruzzenente A, Sandri M, Pachera S, Pedrazzani C, Tasselli S, Iacono C. Radio frequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg. 2007;11:143-149. [PMID: 17390163 DOI: 10.1007/s11605-006-0082-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
205 Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular Carcinoma: Systemic Treatments. Journal of Clinical Gastroenterology 2002;35:S109-14. [DOI: 10.1097/00004836-200211002-00007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
206 Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. The American Journal of Surgery 2012;203:101-6. [DOI: 10.1016/j.amjsurg.2010.09.030] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 6.7] [Reference Citation Analysis]